AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib
AstraZeneca will present data from five pivotal Phase III trials at the ESMO Congress (October 23-27, 2026), with four featured in Presidential Symposia, spanning Sone-Ve, IMFINZI, TAGRISSO and savolitinib. Key highlights include CLARITY-Gastric01, the first Phase III trial to show a statistically significant overall survival benefit for an anti-CLDN18.2 ADC in 2L+ gastric cancer, plus SAFFRON (TAGRISSO + savolitinib in MET-driven EGFRm NSCLC), VOLGA and Amgen-led DeLLphi-305.
Key figures
- Drug Name
- Sone-Ve (sonesitatug vedotin)
- Phase Of Trial
- Phase III
- Abstracts presented
- more than 100
- Pivotal phase3 trials
- 5
- Presidential symposia trials
- 4
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.